Selected research
Industry Research
Anti-obesity Medicine Industry Research Report 2026
Market perspective
The global Anti-obesity Medicine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Anti-obesity Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Anti-obesity Medicine market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Anti-obesity Medicine market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Anti-obesity Medicine include Eisai, Novo Nordisk, Merck, Roche, Pfizer, GlaxoSmithKline, Vivus, Orexigen Therapeutics and Boehringer Ingelheim, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Anti-obesity Medicine market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Anti-obesity Medicine.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-obesity Medicine Market by Company
Eisai
Novo Nordisk
Merck
Roche
Pfizer
GlaxoSmithKline
Vivus
Orexigen Therapeutics
Boehringer Ingelheim
Arena Pharmaceuticals
Amylin Pharmaceuticals
Alizyme
Anti-obesity Medicine Segment by Type
Prescription Drugs
OTC Drugs
Anti-obesity Medicine Segment by Application
Men
Women
Anti-obesity Medicine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-obesity Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-obesity Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-obesity Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Anti-obesity Medicine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prescription Drugs
- OTC Drugs
Applications
- Men
- Women
Companies covered
- Eisai
- Novo Nordisk
- Merck
- Roche
- Pfizer
- GlaxoSmithKline
- Vivus
- Orexigen Therapeutics
- Boehringer Ingelheim
- Arena Pharmaceuticals
- Amylin Pharmaceuticals
- Alizyme
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Anti-obesity Medicine by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Prescription Drugs
- 2.2.3 OTC Drugs
- 2.3 Anti-obesity Medicine by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Men
- 2.3.3 Women
- 2.4 Assumptions and Limitations
3 Anti-obesity Medicine Breakdown Data by Type
- 3.1 Global Anti-obesity Medicine Historic Market Size by Type (2021-2026)
- 3.2 Global Anti-obesity Medicine Forecasted Market Size by Type (2027-2032)
4 Anti-obesity Medicine Breakdown Data by Application
- 4.1 Global Anti-obesity Medicine Historic Market Size by Application (2021-2026)
- 4.2 Global Anti-obesity Medicine Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Anti-obesity Medicine Market Perspective (2021-2032)
- 5.2 Global Anti-obesity Medicine Growth Trends by Region
- 5.2.1 Global Anti-obesity Medicine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Anti-obesity Medicine Historic Market Size by Region (2021-2026)
- 5.2.3 Anti-obesity Medicine Forecasted Market Size by Region (2027-2032)
- 5.3 Anti-obesity Medicine Market Dynamics
- 5.3.1 Anti-obesity Medicine Industry Trends
- 5.3.2 Anti-obesity Medicine Market Drivers
- 5.3.3 Anti-obesity Medicine Market Challenges
- 5.3.4 Anti-obesity Medicine Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Anti-obesity Medicine Players by Revenue
- 6.1.1 Global Top Anti-obesity Medicine Players by Revenue (2021-2026)
- 6.1.2 Global Anti-obesity Medicine Revenue Market Share by Players (2021-2026)
- 6.2 Global Anti-obesity Medicine Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Anti-obesity Medicine Head Office and Area Served
- 6.4 Global Anti-obesity Medicine Players, Product Type & Application
- 6.5 Global Anti-obesity Medicine Manufacturers Established Date
- 6.6 Global Anti-obesity Medicine Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Anti-obesity Medicine Market Size (2021-2032)
- 7.2 North America Anti-obesity Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Anti-obesity Medicine Market Size by Country (2021-2026)
- 7.4 North America Anti-obesity Medicine Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Anti-obesity Medicine Market Size (2021-2032)
- 8.2 Europe Anti-obesity Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Anti-obesity Medicine Market Size by Country (2021-2026)
- 8.4 Europe Anti-obesity Medicine Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Anti-obesity Medicine Market Size (2021-2032)
- 9.2 Asia-Pacific Anti-obesity Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Anti-obesity Medicine Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Anti-obesity Medicine Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Anti-obesity Medicine Market Size (2021-2032)
- 10.2 South America Anti-obesity Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Anti-obesity Medicine Market Size by Country (2021-2026)
- 10.4 South America Anti-obesity Medicine Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Anti-obesity Medicine Market Size (2021-2032)
- 11.2 Middle East & Africa Anti-obesity Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Anti-obesity Medicine Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Anti-obesity Medicine Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Eisai
- 12.1.1 Eisai Company Information
- 12.1.2 Eisai Business Overview
- 12.1.3 Eisai Revenue in Anti-obesity Medicine Business (2021-2026)
- 12.1.4 Eisai Anti-obesity Medicine Product Portfolio
- 12.1.5 Eisai Recent Developments
- 12.2 Novo Nordisk
- 12.2.1 Novo Nordisk Company Information
- 12.2.2 Novo Nordisk Business Overview
- 12.2.3 Novo Nordisk Revenue in Anti-obesity Medicine Business (2021-2026)
- 12.2.4 Novo Nordisk Anti-obesity Medicine Product Portfolio
- 12.2.5 Novo Nordisk Recent Developments
- 12.3 Merck
- 12.3.1 Merck Company Information
- 12.3.2 Merck Business Overview
- 12.3.3 Merck Revenue in Anti-obesity Medicine Business (2021-2026)
- 12.3.4 Merck Anti-obesity Medicine Product Portfolio
- 12.3.5 Merck Recent Developments
- 12.4 Roche
- 12.4.1 Roche Company Information
- 12.4.2 Roche Business Overview
- 12.4.3 Roche Revenue in Anti-obesity Medicine Business (2021-2026)
- 12.4.4 Roche Anti-obesity Medicine Product Portfolio
- 12.4.5 Roche Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Anti-obesity Medicine Business (2021-2026)
- 12.5.4 Pfizer Anti-obesity Medicine Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 GlaxoSmithKline
- 12.6.1 GlaxoSmithKline Company Information
- 12.6.2 GlaxoSmithKline Business Overview
- 12.6.3 GlaxoSmithKline Revenue in Anti-obesity Medicine Business (2021-2026)
- 12.6.4 GlaxoSmithKline Anti-obesity Medicine Product Portfolio
- 12.6.5 GlaxoSmithKline Recent Developments
- 12.7 Vivus
- 12.7.1 Vivus Company Information
- 12.7.2 Vivus Business Overview
- 12.7.3 Vivus Revenue in Anti-obesity Medicine Business (2021-2026)
- 12.7.4 Vivus Anti-obesity Medicine Product Portfolio
- 12.7.5 Vivus Recent Developments
- 12.8 Orexigen Therapeutics
- 12.8.1 Orexigen Therapeutics Company Information
- 12.8.2 Orexigen Therapeutics Business Overview
- 12.8.3 Orexigen Therapeutics Revenue in Anti-obesity Medicine Business (2021-2026)
- 12.8.4 Orexigen Therapeutics Anti-obesity Medicine Product Portfolio
- 12.8.5 Orexigen Therapeutics Recent Developments
- 12.9 Boehringer Ingelheim
- 12.9.1 Boehringer Ingelheim Company Information
- 12.9.2 Boehringer Ingelheim Business Overview
- 12.9.3 Boehringer Ingelheim Revenue in Anti-obesity Medicine Business (2021-2026)
- 12.9.4 Boehringer Ingelheim Anti-obesity Medicine Product Portfolio
- 12.9.5 Boehringer Ingelheim Recent Developments
- 12.10 Arena Pharmaceuticals
- 12.10.1 Arena Pharmaceuticals Company Information
- 12.10.2 Arena Pharmaceuticals Business Overview
- 12.10.3 Arena Pharmaceuticals Revenue in Anti-obesity Medicine Business (2021-2026)
- 12.10.4 Arena Pharmaceuticals Anti-obesity Medicine Product Portfolio
- 12.10.5 Arena Pharmaceuticals Recent Developments
- 12.11 Amylin Pharmaceuticals
- 12.11.1 Amylin Pharmaceuticals Company Information
- 12.11.2 Amylin Pharmaceuticals Business Overview
- 12.11.3 Amylin Pharmaceuticals Revenue in Anti-obesity Medicine Business (2021-2026)
- 12.11.4 Amylin Pharmaceuticals Anti-obesity Medicine Product Portfolio
- 12.11.5 Amylin Pharmaceuticals Recent Developments
- 12.12 Alizyme
- 12.12.1 Alizyme Company Information
- 12.12.2 Alizyme Business Overview
- 12.12.3 Alizyme Revenue in Anti-obesity Medicine Business (2021-2026)
- 12.12.4 Alizyme Anti-obesity Medicine Product Portfolio
- 12.12.5 Alizyme Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst